Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

95.69 -0.55 (-0.57%)
Streaming Delayed Price Updated: 10:44 AM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,551,507
Open 95.95
Bid (Size) 95.68 (2)
Ask (Size) 95.71 (2)
Prev. Close 96.24
Today's Range 95.15 - 96.24
52wk Range 94.48 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 3.22%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Summit Therapeutics Stock Is Jumping Today
Via The Motley Fool
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
Via The Motley Fool
Topics Stocks
Exposures US Equities

Performance

YTD
-3.50%
-3.50%
1 Month
-3.70%
-3.70%
3 Month
-10.26%
-10.26%
6 Month
-23.06%
-23.06%
1 Year
-19.87%
-19.87%

More News

Read More
Earnings Season Scorecard And Fresh Analyst Reports For Chevron, Merck & Others
Via Talk Markets
Topics Stocks / Equities
Healthcare And Biotech Stocks Lag The Market Again
Via Talk Markets
Topics Stocks / Equities
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Exposures Artificial Intelligence
Price Over Earnings Overview: Merck & Co
Via Benzinga
Unpacking the Latest Options Trading Trends in Merck & Co
Via Benzinga
Is NYSE:MRK suited for dividend investing?
Via Chartmill
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
Via Benzinga
Topics Economy
Exposures Interest Rates
Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
From Merck & Co., Inc.
Via Business Wire
3 Magnificent S&P 500 Dividend Stocks Down 25%, 60%, and 26% to Buy and Hold Forever
Via The Motley Fool
Topics Stocks
Exposures US Equities
What Lies Ahead In 2025? Slower Growth, More Volatility
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Via Investor's Business Daily
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Moderna Shares Spike on H5N1 News—What’s Next for Investors?
Via MarketBeat
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Merck’s GARDASIL® Receives Expanded Approval for Males in China
From Merck & Co., Inc.
Via Business Wire
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Via Benzinga
Merck Buys WuXi Vaccines' Irish Manufacturing Facility For Over $500 Million
Via Benzinga
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
Via Benzinga
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Why Viking Therapeutics Stock Plummeted by 24% in December
Via The Motley Fool
Should You Buy the Dip on This High-Flying Stock?
Via The Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.